NBSE Insider Trading Activity and SEC Form 4 Filings
NBSE insider trading summary
No open-market insider purchases or sales of NeuBase Therapeutics, Inc. (NBSE) have been reported on SEC Form 4 in the past 12 months.
Latest NBSE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 18, 2023 | Symetryx Corp | 10% Owner | Sell | $60K (50,000 @ $1.19) |
| Sep 15, 2023 | Symetryx Corp | 10% Owner | Sell | $130K (103,337 @ $1.26) |
| Sep 14, 2023 | Symetryx Corp | 10% Owner | Sell | $186K (129,108 @ $1.44) |
| Sep 11, 2023 | Symetryx Corp | 10% Owner | Sell | $5K (3,376 @ $1.44) |
| Sep 8, 2023 | Symetryx Corp | 10% Owner | Sell | $197K (128,847 @ $1.53) |
| Sep 7, 2023 | Symetryx Corp | 10% Owner | Sell | $135K (74,852 @ $1.80) |
| Sep 1, 2023 | Symetryx Corp | 10% Owner | Buy | $60K (61,076 @ $0.98) |
| Mar 30, 2022 | William Roland Mann | Chief Operating Officer | Buy | $12K (6,200 @ $1.92) |
| Mar 18, 2022 | Todd P. Branning | Chief Financial Officer | Buy | $18K (10,000 @ $1.81) |
| Mar 17, 2022 | Todd P. Branning | Chief Financial Officer | Buy | $17K (10,000 @ $1.74) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.